Trial Profile
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Volixibat (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Shire
- 28 Mar 2020 Interim results (n=80) at week 24 assessing efficacy of volixibat in adults with non-alcoholic steatohepatitis, published in the Journal of Hepatology.
- 15 Apr 2019 According to a Mirum Pharmaceuticals media release, 24-week interim analysis results from this study were presented at the The International Liver Congress 2019 (at the Liver Unit, Queen Elizabeth Hospital, Birmingham).
- 15 Apr 2019 Interim analysis results (24-week ) from this study presented in a Mirum Pharmaceuticals media release.